Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report.
1 Pharmacological and experimental studies have shown that ibopamine (SB 7505, di-isobutyric ester of N-methyldopamine) is capable of increasing renal blood flow, diuresis, urinary sodium, potassium and creatinine excretion. 2 SB 7505 was given to twelve volunteer patients, six of whom had normal renal function and six with various degrees of chronic renal impairment. 3 In both groups the drug yielded a prompt increase in urinary excretion of water, sodium and potassium, while creatinine clearance was also seen to increase. 4 Heart rate and arterial pressure were unaffected by SB 7505 in all patients. 5 Results seen encouraging and call for further study on the proper use of the drug in clinical nephrology.
D000328:Adult; D000368:Aged; D001835:Body Weight; D003404:Creatinine / Q000097:blood; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D005919:Glomerular Filtration Rate; D006439:Hemodynamics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D011188:Potassium / Q000652:urine
C023487:ibopamine; D003404:Creatinine; D003846:Deoxyepinephrine; D011188:Potassium; D004298:Dopamine